| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2012 | WO2012012372A1 Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha |
| 01/26/2012 | WO2012012370A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/26/2012 | WO2012012347A2 Methods of intravenous administration of glyburide and other drugs |
| 01/26/2012 | WO2012012339A2 Glycosylated acetaminophen pro-drug analogs |
| 01/26/2012 | WO2012012333A1 Topical treatment of neuropathic pain and methods of diagnosis |
| 01/26/2012 | WO2012012322A1 Substituted hydroxamic acids and uses thereof |
| 01/26/2012 | WO2012012314A1 Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| 01/26/2012 | WO2012012307A1 Sulfonyl compounds which modulate the cb2 rece |
| 01/26/2012 | WO2012012305A2 Combination therapy using a ruthenium complex |
| 01/26/2012 | WO2012012304A2 Method of treating refractory cancer |
| 01/26/2012 | WO2012012300A2 Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | WO2012012278A2 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | WO2012012264A1 Methods and compositions for the treatment of allergy |
| 01/26/2012 | WO2012012257A2 BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING Aβ OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE |
| 01/26/2012 | WO2012012184A2 Ophthalmic devices containing chemokine antagonists |
| 01/26/2012 | WO2012012156A1 Methods and compositions for the improvement of skeletal muscle function in a mammal |
| 01/26/2012 | WO2012012147A2 Methods and compositions for treatment of multiple sclerosis |
| 01/26/2012 | WO2012012139A1 Synthesis and use of kinase inhibitors |
| 01/26/2012 | WO2012012072A1 Cosmetic use of substituted 2-(2-benzyl-1-benzimidazoyl) analogs and related compounds |
| 01/26/2012 | WO2012011917A1 Administration of rifalazil to immunocompromised patients |
| 01/26/2012 | WO2012011882A1 A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases |
| 01/26/2012 | WO2012011876A1 Methods for identifying candidate cytotoxic antibody molecules |
| 01/26/2012 | WO2012011875A1 Compounds for photodynamic therapy |
| 01/26/2012 | WO2012011847A1 Substituted indoles, antiviral active component, method for producing and using same |
| 01/26/2012 | WO2012011840A1 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same |
| 01/26/2012 | WO2012011752A2 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity |
| 01/26/2012 | WO2012011741A2 Novel fusarisetin compounds, and use thereof |
| 01/26/2012 | WO2012011740A2 Method for preparing microspheres and microspheres produced thereby |
| 01/26/2012 | WO2012011707A2 Substituted pyridinone derivatives and methods for manufacturing the same |
| 01/26/2012 | WO2012011673A2 Pharmaceutical composition including hesperetin as an active ingredient for promoting muscle cell differentiation or renewal |
| 01/26/2012 | WO2012011619A1 Method for separating ephedrine from ephedra sinica stapf at a high yield, and adjuvant for enhancing immunity containing ephedrine as an active ingredient |
| 01/26/2012 | WO2012011592A1 Heterocyclic compound and application thereof |
| 01/26/2012 | WO2012011591A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | WO2012011588A1 Oral medicinal composition for patients undergoing peritoneal dialysis and method for using same |
| 01/26/2012 | WO2012011572A1 Therapeutic agent for diastolic heart failure |
| 01/26/2012 | WO2012011566A1 Tacrolimus-containing oil-in-water type creamy composition |
| 01/26/2012 | WO2012011549A1 P2x4 receptor antagonist |
| 01/26/2012 | WO2012011548A1 Nitrogen-containing heterocyclic derivative |
| 01/26/2012 | WO2012011314A1 Benzofuranone compound and pharmaceutical composition containing same |
| 01/26/2012 | WO2012011192A1 Tacrolimus-containing oil-in-water type creamy composition |
| 01/26/2012 | WO2012011174A1 Lipid metabolism improving agent, agent for enhancing lipid metabolism improving action, anti-obesity agent, and agent for enhancing anti-obesity action |
| 01/26/2012 | WO2012011128A1 Preparation of prostaglandin derivatives |
| 01/26/2012 | WO2012011125A1 Agonists of gpr40 |
| 01/26/2012 | WO2012011123A1 Pyridin- 2 - yl sulfanyl acid esters and process for the preparation thereof |
| 01/26/2012 | WO2012011118A2 Development of a fixed dose combination dosage form containing ramipril and carvedilol |
| 01/26/2012 | WO2012011112A1 Non psychoactive cannabinoids and uses thereof |
| 01/26/2012 | WO2012011103A2 METHODS AND COMPOSITIONS FOR INHIBITING THE NUCLEAR FACTOR kB PATHWAY |
| 01/26/2012 | WO2012011081A1 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics |
| 01/26/2012 | WO2012011063A1 Polydeoxyribonucleotides (pdrns) for use in the treatment of metabolic and/or lactic acidosis and polydeoxyribonucleotide-based compositions for the aforesaid use |
| 01/26/2012 | WO2012010977A2 Single daily dosage form for prevention and treatment of metabolic syndrome |
| 01/26/2012 | WO2012010942A2 Novel pharmaceutical composition(s) of hiv protease inhibitor(s) |
| 01/26/2012 | WO2012010938A2 Pharmaceutical compositions of cefditoren pivoxil |
| 01/26/2012 | WO2012010896A1 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
| 01/26/2012 | WO2012010883A2 Pharmaceutical depot for 5-fluoro-2 [ [ (1s) -1- (5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile |
| 01/26/2012 | WO2012010854A1 Inhalation formulations comprising carmoterol in combination with a corticosteroid |
| 01/26/2012 | WO2012010826A1 Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them |
| 01/26/2012 | WO2012010802A1 Process for preparing benzofuran derivatives substituted at position 5 |
| 01/26/2012 | WO2012010704A1 New aminopyrazoloquinazolines |
| 01/26/2012 | WO2012010701A1 Composition for the treatment of botulism |
| 01/26/2012 | WO2012010674A1 Nkx2.2 inhibitors as drugs |
| 01/26/2012 | WO2012010669A2 Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer |
| 01/26/2012 | WO2012010663A1 2,3,5-trisubstituted thiophene compounds and uses thereof |
| 01/26/2012 | WO2012010644A1 Process for the synthesis of isothiocyanates and derivatives thereof and uses of same |
| 01/26/2012 | WO2012010641A2 Pharmaceutical composition for increasing cellular hypoxic tolerance |
| 01/26/2012 | WO2012010616A1 Medicaments based on dinuclear arene ruthenium complexes comprising bridging thiolato, selenolato or alkoxo ligands |
| 01/26/2012 | WO2012010606A1 Hexacyclic polyketides as kinase inhibitors |
| 01/26/2012 | WO2012010578A1 Substituted methyl-pyrimidin-5-yl carbamates and use thereof |
| 01/26/2012 | WO2012010577A1 Substituted oxazolidinones and oxazinanones and use thereof |
| 01/26/2012 | WO2012010576A1 Carbamate-substituted diaminopyrimidines and use thereof |
| 01/26/2012 | WO2012010571A1 Dronedarone for the prevention of cardiovascular hospitalization or of mortality in patients with lone atrial fibrillation |
| 01/26/2012 | WO2012010555A1 Tricyclic lactones for treatment of cancer |
| 01/26/2012 | WO2012010478A1 Combination of siloxane and active ingredient for treating dental disorder |
| 01/26/2012 | WO2012010415A1 Pharmaceutical composition containing a tryptophan derivative |
| 01/26/2012 | WO2012010413A1 Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
| 01/26/2012 | WO2012010316A1 Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| 01/26/2012 | WO2012010276A1 Derivatives of 1,4-dihydropyridine possessing antiviral efficacy |
| 01/26/2012 | WO2012010159A1 Biodegradable nano-, meso-, and micro-polymer particles for maintaining a low surface tension in the lung and for protecting the pulmonary surfactant |
| 01/26/2012 | WO2012010091A1 Optically pure quinazoline compound |
| 01/26/2012 | WO2012010089A1 Preparation method for and uses of carboprost tromethamine crystal |
| 01/26/2012 | WO2012010088A1 Optically pure quinazoline compounds |
| 01/26/2012 | WO2012010022A1 New use of hesperetin |
| 01/26/2012 | WO2012009973A1 Antiparkinsonian drug-loaded microsphere composition and use thereof |
| 01/26/2012 | WO2012009961A1 Use of a fermented soy extract for manufacture of a prebiotic composition |
| 01/26/2012 | WO2012009852A1 Method of coating an inorganic substrate with a stable organic layer |
| 01/26/2012 | WO2012009823A1 Tranquilising/sedating pharmaceutical formulation based on neurosteroids and a phenothiazine derivative for use in mammals |
| 01/26/2012 | WO2011156811A3 Compounds for treatment of bovine mastitis |
| 01/26/2012 | WO2011156655A3 Novel glp-1 receptor stabilizers and modulators |
| 01/26/2012 | WO2011156248A3 Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| 01/26/2012 | WO2011153545A3 Gene expression signature as a predictor of chemotherapeutic response in breast cancer |
| 01/26/2012 | WO2011152730A3 Stable high lipid liquid formula |
| 01/26/2012 | WO2011151840A3 Compositions comprising non-acidic boswellia oil fraction as a bio-enhancer for enhancing the bioavailability of biological agents |
| 01/26/2012 | WO2011151786A3 Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer |
| 01/26/2012 | WO2011150457A3 Haematopoietic-prostaglandin d2 synthase inhibitors |
| 01/26/2012 | WO2011147028A3 Apple skin extracts for treating cardiovascular disease |
| 01/26/2012 | WO2011147026A3 A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| 01/26/2012 | WO2011139489A3 Compounds that modulate intracellular calcium |
| 01/26/2012 | WO2011135585A3 Aqueous pharmaceutical solution of ciclesonide |
| 01/26/2012 | WO2011132901A3 Novel benzamide derivatives |
| 01/26/2012 | WO2011132114A9 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment |
| 01/26/2012 | WO2011127406A3 Acridines as inhibitors of haspin and dyrk kinases |